Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma

Nuclear Medicine and Biology

Volumn 38, Issue 2, 2011, Pages 151-157

  Yoshii, Yukie ^a   Furukawa, Takako ^b   Kiyono, Yasushi ^a   Watanabe, Ryo ^a   Mori, Tetsuya ^a   Yoshii, Hiroshi ^a   Asai, Tatsuya ^a   Okazawa, Hidehiko ^a   Welch, Michael J ^c   Fujibayashi, Yasuhisa ^a,b  

^a UNIVERSITY OF FUKUI   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

64Cu ATSM; Cancer stem cell; CD133; Highly tumorigenic cells; Hypoxia; Internal radiotherapy

Indexed keywords

CD133 ANTIGEN; COPPER DIACETYL BIS (N4 METHYLTHIOSEMICARBAZONE) CU 64; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENIC ACTIVITY; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; TREATMENT DURATION; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COLONIC NEOPLASMS; COPPER RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; PEPTIDES; THIOSEMICARBAZONES; TUMOR BURDEN;

EID: 79551681223     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.08.009     Document Type: Article

References (40)

1. Brown J.M. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999, 59:5863-5870.
2. Dehdashti F., Grigsby P.W., Mintun M.A., Lewis J.S., Siegel B.A., Welch M.J. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55:1233-1238.
3. Dehdashti F., Mintun M.A., Lewis J.S., Bradley J., Govindan R., Laforest R., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
4. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997, 38:1155-1160.
5. Lewis J.S., McCarthy D.W., McCarthy T.J., Fujibayashi Y., Welch M.J. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999, 40:177-183.
6. Takahashi N., Fujibayashi Y., Yonekura Y., Welch M.J., Waki A., Tsuchida T., et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000, 14:323-328.
7. Lewis J.S., Sharp T.L., Laforest R., Fujibayashi Y., Welch M.J. Tumor uptake of copper-diacetyl-bis(N4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001, 42:655-661.
8. Grigsby P.W., Malyapa R.S., Higashikubo R., Schwarz J.K., Welch M.J., Huettner P.C., et al. Comparison of molecular markers of hypoxia and imaging with 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007, 9:278-283.
9. Obata A., Yoshimi E., Waki A., Lewis J.S., Oyama N., Welch M.J., et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001, 15:499-504.
10. Burgman P., O'Donoghue J.A., Lewis J.S., Welch M.J., Humm J.L., Ling C.C. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005, 32:623-630.
11. Dearling J.L., Lewis J.S., Mullen G.E., Welch M.J., Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002, 7:249-259.
12. Holland J.P., Giansiracusa J.H., Bell S.G., Wong L.L., Dilworth J.R. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol 2009, 54:2103-2119.
13. Dehdashti F., Grigsby P.W., Lewis J.S., Laforest R., Siegel B.A., Welch M.J. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49:201-205.
14. Dietz D.W., Dehdashti F., Grigsby P.W., Malyapa R.S., Myerson R.J., Picus J., et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008, 51:1641-1648.
15. Obata A., Kasamatsu S., McCarthy D.W., Welch M.J., Saji H., Yonekura Y., et al. Production of therapeutic quantities of 64Cu using a 12 MeV cyclotron. Nucl Med Biol 2003, 30:535-539.
16. Lewis J., Laforest R., Buettner T., Song S., Fujibayashi Y., Connett J., et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci USA 2001, 98:1206-1211.
17. Obata A., Kasamatsu S., Lewis J.S., Furukawa T., Takamatsu S., Toyohara J., et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol 2005, 32:21-28.
18. Kroger L.A., DeNardo G.L., Gumerlock P.H., Xiong C.Y., Winthrop M.D., Shi X.B., et al. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm 2001, 16:213-225.
19. Connett J.M., Anderson C.J., Guo L.W., Schwarz S.W., Zinn K.R., Rogers B.E., et al. Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Proc Natl Acad Sci USA 1996, 93:6814-6818.
20. Aft R.L., Lewis J.S., Zhang F., Kim J., Welch M.J. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-d-glucose. Cancer Res 2003, 63:5496-5504.
21. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-1261.
22. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006, 66:1883-1890. [discussion 95-6].
23. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
24. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
25. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
26. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
27. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
28. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006, 351:820-824.
29. Wright M.H., Calcagno A.M., Salcido C.D., Carlson M.D., Ambudkar S.V., Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10:R10.
30. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van Buren G., et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009, 69:1951-1957.
31. Maeda S., Shinchi H., Kurahara H., Mataki Y., Maemura K., Sato M., et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98:1389-1397.
32. Tavaluc R.T., Hart L.S., Dicker D.T., El-Deiry W.S. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle 2007, 6:2554-2562.
33. Zhou J., Zhang Y. Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle 2008, 7:1360-1370.
34. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
35. Liu G., Yuan X., Zeng Z., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
36. Yoshii Y., Furukawa T., Kiyono Y., Watanabe R., Waki A., Mori T., et al. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol 2010, 37:395-404.
37. Janik P., Briand P., Hartmann N.R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 1975, 35:3698-3704.
38. Ieta K., Tanaka F., Haraguchi N., Kita Y., Sakashita H., Mimori K., et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008, 15:638-648.
39. Shmelkov S.V., Butler J.M., Hooper A.T., Hormigo A., Kushner J., Milde T., et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120.
40. Roy K., Kodama S., Suzuki K., Watanabe M. Delayed cell death, giant cell formation and chromosome instability induced by X-irradiation in human embryo cells. J Radiat Res (Tokyo) 1999, 40:311-322.